Abrilada
Nov 19, 2019
Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod
Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be inv...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
